Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 4, Issue 5, Pages 513-531Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425247.4.5.513
Keywords
DepoFoam (TM); dendrimers; inclusion complexes; liposomes; microparticles; nanoparticles; polymeric micelles; polyplex nanogels; Stealth (R) particles; vesicular phospholipid gel
Categories
Ask authors/readers for more resources
Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available